Details of Drug

Details of Drug

 Drug General Information (ID: D0434)
  Drug Name
Deferoxamine
  Drug Type Small molecule
  Drug Synonymous
deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; 70-51-9; Deferrioxamine; Deferoxamin; Deferoxaminum; DFOM; Desferin; Desferral; Desferrin; Desferex; Desferan; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; Desferriferrioxamin B; UNII-J06Y7MXW4D; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina ; Deferoxamine
    Click to Show/Hide
  Disease Class 1D64-1D65: COVID-19
  Therapeutic Class Antiviral Agents
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C25H48N6O8
  InChI 1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)
  InChIKey UBQYURCVBFRUQT-UHFFFAOYSA-N
  Canonical SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
  External Link
Pubchem ID 2973
CAS Number 70-51-9
CHEBI ID 4356
TTD ID D06GKR

Drug-Drug Interaction Network
  Sunburst Graph
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
BM027  Decreased renal excretion due to nephrotoxicity
BM072  Increased risk of nephrotoxicity
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Deferoxamine
      Affected excretion pathways
   Decreased renal excretion due to nephrotoxicity Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1389
 
Remdesivir
 
C27H35N6O8P
 
121304016 
Moderate    Inter Info   
[15], [2], [16], [17], [18]
      Pharmacodynamic additive effects
   Increased risk of nephrotoxicity Drug Num:  12
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0335
 
Cidofovir
 
C8H14N3O6P
 
60613 
Major    Inter Info   
[1]
D0805
 
Inotersen
 
C230H318N69O121P19S19
 
121492004 
Major    Inter Info   
[2], [3]
D0831
 
Iodipamide
 
C20H14I6N2O6
 
3739 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0832
 
Iodixanol
 
C35H44I6N6O15
 
3724 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0833
 
Iohexol
 
C19H26I3N3O9
 
3730 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0834
 
Iopamidol
 
C17H22I3N3O8
 
65492 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0836
 
Iopromide
 
C18H24I3N3O8
 
3736 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0837
 
Iothalamic acid
 
C11H9I3N2O4
 
3737 
Major    Inter Info   
[6], [7], [8]
D0838
 
Ioversol
 
C18H24I3N3O9
 
3741 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0839
 
Ioxilan
 
C18H24I3N3O8
 
3743 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0472
 
Diatrizoate
 
C11H9I3N2O4
 
2140 
Major    Inter Info   
[4], [5], [6], [7], [8], [9], [10]
D0357
 
Clofarabine
 
C10H11ClFN5O3
 
119182 
Moderate    Inter Info   
[14]
   Increased risk of other adverse reactions (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1694
 
Vigabatrin
 
C6H11NO2
 
5665 
Major    Inter Info   
[11], [12], [13]
References
1 Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
2 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3 Product Information. Tegsedi (inotersen). Akcea Therapeutics, Cambridge, MA.
4 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
5 Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56. [PMID: 2407013]
6 Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
7 Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7. [PMID: 25652747]
8 Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001. [PMID: 19445797]
9 Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6. [PMID: 22174040]
10 van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70. [PMID: 16137385]
11 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
12 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
13 Product Information. Sabril (vigabatrin). Lundbeck Inc, Deerfield, IL.
14 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
15 Cerner Multum, Inc. "Australian Product Information.".
16 European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
17 Gilead Sciences, Inc "About Remdesivir.".
18 US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".